TISIDB

Summary
Symbol	MYO18A
Name	myosin XVIIIA
Aliases	KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location	17q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Endoplasmic reticulum-Golgi intermediate compartment Cytoplasm, cytoskeleton. Note=Colocalizes with actin.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Note=Lacks the PDZ domain. Diffusely localized in the cytoplasm.; SUBCELLULAR LOCATION: Golgi apparatus. Golgi apparatus, trans-Golgi network. Note=Recruited to the Golgi apparatus by GOLPH3.; SUBCELLULAR LOCATION: Isoform 5: Cell surface
Domain	PF00063 Myosin head (motor domain) PF01576 Myosin tail PF00595 PDZ domain (Also known as DHR or GLGF)
Function	May link Golgi membranes to the cytoskeleton and participate in the tensile force required for vesicle budding from the Golgi. Thereby, may play a role in Golgi membrane trafficking and could indirectly give its flattened shape to the Golgi apparatus (PubMed:19837035, PubMed:23345592). Alternatively, in concert with LURAP1 and CDC42BPA/CDC42BPB, has been involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration (PubMed:18854160). May be involved in the maintenance of the stromal cell architectures required for cell to cell contact (By similarity). Regulates trafficking, expression, and activation of innate immune receptors on macrophages. Plays a role to suppress inflammatory responsiveness of macrophages via a mechanism that modulates CD14 trafficking (PubMed:25965346). Acts as a receptor of surfactant-associated protein A (SFTPA1/SP-A) and plays an important role in internalization and clearance of SFTPA1-opsonized S.aureus by alveolar macrophages (PubMed:16087679, PubMed:21123169). Strongly enhances natural killer cell cytotoxicity (PubMed:27467939).

> Gene Ontology [ TOP ]
Biological Process	GO:0006900 membrane budding GO:0007030 Golgi organization GO:0007163 establishment or maintenance of cell polarity GO:0009306 protein secretion GO:0016050 vesicle organization GO:0030010 establishment of cell polarity GO:0031032 actomyosin structure organization GO:0048193 Golgi vesicle transport GO:0048194 Golgi vesicle budding GO:0050708 regulation of protein secretion GO:0050714 positive regulation of protein secretion GO:0051047 positive regulation of secretion GO:0051222 positive regulation of protein transport GO:0090161 Golgi ribbon formation GO:0090162 establishment of epithelial cell polarity GO:0090164 asymmetric Golgi ribbon formation GO:1903532 positive regulation of secretion by cell GO:1904951 positive regulation of establishment of protein localization
Molecular Function	GO:0003779 actin binding GO:0043531 ADP binding GO:0051015 actin filament binding
Cellular Component	GO:0005793 endoplasmic reticulum-Golgi intermediate compartment GO:0005802 trans-Golgi network GO:0015629 actin cytoskeleton GO:0016459 myosin complex GO:0031984 organelle subcompartment GO:0042641 actomyosin GO:0098791 Golgi subcompartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-1839124: FGFR1 mutant receptor activation R-HSA-1226099: Signaling by FGFR in disease R-HSA-5655302: Signaling by FGFR1 in disease R-HSA-1839117: Signaling by cytosolic FGFR1 fusion mutants

Summary
Symbol	MYO18A
Name	myosin XVIIIA
Aliases	KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location	17q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MYO18A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MYO18A
Name	myosin XVIIIA
Aliases	KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location	17q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MYO18A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MYO18A
Name	myosin XVIIIA
Aliases	KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location	17q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MYO18A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.664	0.0128
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.695	0.678
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.639	0.617
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.136	0.688
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.307	0.913
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.084	0.982
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.464	0.169
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.512	0.74
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.362	0.84
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.828	0.609
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.298	0.574
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.124	0.105

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MYO18A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	4.1	-4.1	0.561
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	5.1	-5.1	0.549
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	13.2	3.7	9.5	0.388
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	7.7	5.9	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	0	12.5	0.485
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MYO18A
Name	myosin XVIIIA
Aliases	KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location	17q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYO18A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MYO18A
Name	myosin XVIIIA
Aliases	KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location	17q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYO18A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYO18A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MYO18A
Name	myosin XVIIIA
Aliases	KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location	17q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYO18A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MYO18A
Name	myosin XVIIIA
Aliases	KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location	17q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MYO18A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MYO18A
Name	myosin XVIIIA
Aliases	KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location	17q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MYO18A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MYO18A
Name	myosin XVIIIA
Aliases	KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location	17q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MYO18A collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MYO18A